Últimas noticias sobre Harvard Bioscience (NASDAQ:HBIO) Bolsa

Harvard Bioscience

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.

Harvard Bioscience Inc

<h3>Gainers</h3>
<ul>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares moved upwards by 36.8% to $1.98 during Thursday's regular session. The market value of their outstanding shares is at $43.6 million. As per the news, the Q2 earnings report came out today. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares moved upwards by 31.25% to $0.95. The market value of their outstanding shares is at $109.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares increased by 30.76% to $12.03. The market value of their outstanding shares is at $630.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 29.17% to $0.71. The market value of their outstanding shares is at $10.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 23.03% to $0.08. The market value of their outstanding shares is at $4.0 million. </li>
<li>Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) shares rose 19.61% to $5.0. The company's market cap stands at $151.1 million. As per the press release, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares fell 28.7% to $0.92 during Thursday's regular session. The company's market cap stands at $40.4 million. </li>
<li>Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares fell 24.69% to $18.06. The company's market cap stands at $3.6 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) shares declined by 19.54% to $4.49. The market value of their outstanding shares is at $296.0 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) shares decreased by 17.75% to $12.61. The company's market cap stands at $552.6 million. The company's, Q3 earnings came out today. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares fell 17.56% to $2.33. The market value of their outstanding shares is at $101.3 million. As per the press release, Q3 earnings came out today. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares decreased by 16.41% to $3.64. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AXGN

CELU

CHRS

CLOV

ENSC

HBIO

PSNL

XRAY

12 Health Care Stocks Moving In Thursday's Intraday Session

News

Guidance

Harvard Bioscience Sees Q4 Revenue $23M-$26M

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.03 by 166.67 percent. The company reported quarterly sales of $22.000 million which missed the analyst consensus estimate of $25.300 million by 13.04 percent. This is a 13.26 percent decrease over sales of $25.363 million the same period last year.

Earnings

Earnings Misses

Harvard Bioscience Q3 2024 Adj. EPS $(0.02) Misses $0.03 Estimate, Sales $22.000M Miss $25.300M Estimate

The Company expects 2024 full year gross margin of approximately&nbsp;59%&nbsp;to&nbsp;60%&nbsp;and adjusted EBITDA margin in the high single digits.

Harvard Bioscience Cuts FY24 Revenue Outlook To $97M - $102M ($111.95M), In Light Of Delayed Market Recovery (Prior Outlook: Flat Y/Y)

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) reported quarterly earnings of $0.00 per share which missed the analyst consensus estimate of $0.05 by 98 percent. This is a 97.5 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $23.097 million which missed the analyst consensus estimate of $26.400 million by 12.51 percent. This is a 19.69 percent decrease over sales of $28.759 million the same period last year.

Harvard Bioscience Q2 2024 Adj. EPS $0.00 Misses $0.05 Estimate, Sales $23.097M Miss $26.400M Estimate

The Dow Jones index closed lower by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Harvard Bioscience</h3>
<ul>
<li>The Trade: Harvard Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) CEO James W Green <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 10,000 shares</a> at an average price of $2.91. To acquire these shares, it cost around $29,100.</li>
<li>What's Happening: On May 7, Harvard Bioscience posted weaker-than-expected quarterly sales.</li>
<li>What Harvard Bioscience Does: Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development.</li>
</ul>
<h3 class="wp-block-heading">Sypris Solutions</h3>
<ul>
<li>The Trade: Sypris Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYPR#NASDAQ">SYPR</a>) Director Gary L Convis <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 20,000 shares at </a>an average price of $1.92. To acquire these shares, it cost around $38,400.</li>
<li>What's Happening: On June 3, Sypris named Michael D. Sedgwick as Vice President and General Manager of Sypris Electronics, LLC.</li>
<li>What Sypris Solutions Does: Sypris Solutions Inc is a USA-based company engaged in providing truck components, oil and gas pipeline components, and aerospace and defense electronics.</li>
</ul>
<h3 class="wp-block-heading">Holley</h3>
<ul>
<li>The Trade: Holley Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) Exec. Chairman of the Board Matthew E Rubel <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 14,493 shares</a> at an average price of $3.39. The insider spent around $49,131 to buy those shares. </li>
<li>What's Happening: On June 4, Telsey Advisory Group analyst Joseph Feldman maintained Holley with an Outperform and maintained a $6.5 price target.</li>
<li>What Holley Does: Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/06/39331770/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Tech Stocks With Over 3% Dividend Yields</a>

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

HLLY

SYPR

Holley And 2 Other Stocks Under $5 Insiders Are Buying

The Dow Jones index closed lower by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Harvard Bioscience</h3>
<ul>
<li>The Trade: Harvard Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) CEO James W Green <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 20,000 shares</a> at an average price of $3.07. To acquire these shares, it cost around $61,400.</li>
<li>What's Happening: On May 7, Harvard Bioscience posted weaker-than-expected quarterly sales.</li>
<li>What Harvard Bioscience Does: Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development.</li>
</ul>
<h3 class="wp-block-heading">EZFill Holdings</h3>
<ul>
<li>The Trade: EZFill Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZFL#NASDAQ">EZFL</a>) 10% owner Michael D Farkas <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 10,000 shares at</a> an average price of $2.10. To acquire these shares, it cost around $20,985.</li>
<li>What's Happening: On May 15, EzFill Holdings posted a narrower loss&nbsp; for the first quarter.</li>
<li>What EZFill Holdings Does: EzFill Holdings Inc is an application-based on-demand fuel delivery company in Florida and a mobile fueling company that combines on-demand fills and subscription services that fill customer vehicles on routine intervals.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39226661/top-4-tech-stocks-that-may-explode-this-month">Top 4 Tech Stocks That May Explode This Month</a>
<h3 class="wp-block-heading">Air Industries Group</h3>
<ul>
<li>The Trade: Air Industries Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIRI#NYSE">AIRI</a>) President Luciano M Melluzzo <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 11,082 shares</a> at an average price of $3.64. The insider spent around $40,283 to buy those shares. </li>
<li>What's Happening: On May 15, Air Industries Group reported better-than-expected first-quarter sales results.</li>
<li>What Air Industries Group Does: Air Industries Group is an aerospace and defense company.</li>
</ul>
<h3 class="wp-block-heading">FlexShopper</h3>
<ul>
<li>The Trade: FlexShopper, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FPAY#NASDAQ">FPAY</a>) Director Howard Dvorkin <a href="https://www.benzinga.com/quote/FPAY/analyst-ratings">acquired a total of 75,346 shares</a> at an average price of $1.10. The insider spent around $83,112 to buy those shares.</li>
<li>What's Happening: On May 13, FlexShopper posted upbeat quarterly sales.</li>
<li>What FlexShopper Does: FlexShopper Inc is a financial technology company engaged in providing certain types of durable goods to consumers on a lease-to-own basis and providing lease-to-own (LTO) terms to consumers of third-party retailers and e-tailers.</li>
</ul>
Don&#8217;t forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

AIRI

EZFL

FPAY

FlexShopper And 3 Other Stocks Under $5 Insiders Are Buying

For the full year 2024 revenues to be approximately flat versus 2023. Company sees second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in China. The company seest 2024 gross margin of approximately 60% and adjusted EBITDA margin in the mid-teens.

Harvard Bioscience Continues To Expect 2024 Gross Margin Of Approximately 60% And Adjusted EBITDA Margin In The Mid-teens

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 66.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $24.51 million which missed the analyst consensus estimate of $25.79 million by 4.96 percent. This is a 18.23 percent decrease over sales of $29.98 million the same period last year.

Harvard Bioscience Q1 Adj $0.02, Inline, Sales $24.51M Miss $25.79M Estimate

Harvard Bioscience Expects Overall Run Rate Savings Of ~$4M Beginning In Q2 2024; Expects Q2 Restructuring-Related Charges Of ~$0.5M

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) reported quarterly earnings of Adj $0.04 per share which missed the analyst consensus estimate of $0.05 by 20 percent. This is unchanged from the same period last year. The company reported quarterly sales of $28.15 million which missed the analyst consensus estimate of $29.11 million by 3.29 percent. This is a 0.96 percent decrease over sales of $28.43 million the same period last year.

Harvard Bioscience Q4 Adj EPS $0.04 Misses $0.05 Estimate, Sales $28.15M Miss $29.11M Estimate

AFCG

ALIM

AMTX

AOUT

ARBE

ARCT

ARHS

ASLE

ASPS

AVGO

BBAI

BBCP

BILI

BITF

BNED

BURL

CHMI

CIEN

CINT

CLAR

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

COOK

COST

CTOS

DBVT

DLTH

DOCU

DOMO

DSGR

DXPE

ELUT

EOLS

EVGN

EYPT

FCEL

FNKO

GEVO

GIFI

GRND

GRNT

GWRE

ISDR

JYNT

LCTX

LMNR

LOCO

LUMO

LVRO

METC

MGNX

MKFG

MRVL

NAPA

NCSM

NDLS

NEPH

NINE

ONCT

ONCY

OPFI

OPTN

OWLT

PBPB

PHAT

PMTS

PRCH

PowerShares Dynamic Industrials Sector Portfolio

PROF

PRTS

PSFE

RDVT

REAX

REFR

RWAY

SDPI

SGHT

Earnings Scheduled For March 7, 2024

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-07. Here's what investors need to know before the announcement.
Analysts estimate that Harvard Bioscience will report an earnings per share (EPS) of $0.05. 
Harvard Bioscience bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.03, which was followed by a 1.41% drop in the share price the next day.
Here's a look at Harvard Bioscience's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.04</td>
<td>0.05</td>
<td>0.05</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.01</td>
<td>0.04</td>
<td>0.06</td>
<td>0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>6.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709755299_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Harvard Bioscience were trading at $4.19 as of March 05. Over the last 52-week period, shares are up 60.9%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HBIO/earnings">To track all earnings releases for Harvard Bioscience visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Harvard Bioscience's Earnings

Harvard Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) today announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 11-13, 2024, in Salt Lake City. Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.
DSI&#x2122; Ponemah&#x2122; Data Management Platform Provides Integrated Preclinical Solution
The Company's industry-leading GLP-compliant Ponemah&#x2122; preclinical data management platform now includes integrations with the new SoHo&#x2122; implantable telemetry solution and the VivaMARS&#x2122; high-capacity behavior monitoring system.
By integrating these new applications in a single data management platform, the Ponemah system provides users with a powerful tool for managing and analyzing data across a range of studies. The integrated platform also opens new opportunities for the use of emerging machine learning-based algorithms to efficiently analyze large data pools.
SoHo&#x2122; Implantable Real-Time Telemetry for Small Animal Models
Together with the Ponemah platform, the SoHo telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in a more natural shared housing environment. In addition, the SoHo solution allows data to be collected over longer time periods and opens exciting new opportunities for longitudinal studies. SoHo supports the customer's business needs by reducing operating costs and test cycle times, enabling increased testing throughput. For more information visit the DSI website at <a href="https://www.globenewswire.com/Tracker?data=V8ttPoHOw-EWSx9Um07ZYwe5VlppD0o8MJ4X2v5N4thoMRS7kenOSrZex0VFi96EA6yM8NDG-PafowI5SJp-3OtHBoLUu0RK2iXHGbpjsbNVjg-nfLZ0vqi6dFm4XZxEvouSUL8oBEwZFXR38dntXueYlATD9BM14JC0frFcJI4-NSS2jPfQQvxzQEGG2lTyUIHX1gUNz2aFXB4bUbqsxJ6z3YO5XdIhOn4UeSm7rNE=">https://www.datasci.com/products/implantable-telemetry/soho-telemetry-system</a>.
VivaMARS&#x2122; Activity Monitoring System
The VivaMARS system combines the Company's infrared Panlab&#xAE; activity monitoring technology with its Ponemah platform to create an integrated, GLP-compliant solution for real-time, high precision behavioral testing. The system is ideally suited to meet the high throughput, automated neuropharmacology and neurotoxicology testing needs of CROs and pharma companies, in addition to longitudinal behavior studies carried out by leading research and academic institutes. For more information on the VivaMARS system, visit the DSI website at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=V8ttPoHOw-EWSx9Um07ZYwe5VlppD0o8MJ4X2v5N4tgnf4OLdDHWo1EVNiwqhpgG9wIRACGAhPJeJgbGe7__G-8MikHmP8Fplwo9hIfJaqcQuvuRqDwZH0y4vLCKztBqthAsA61bf7X6sAEn2iTiDN2Ht1gN2NAhN2HswodVQj5nXZEUpCy9hXUxBMg9QDSFMgU1srjZyIcatryzSvcrPQ6sPO05il-x28H_EowzV5SP-2OmL7kC7azRdUJytqF0G-mhE06sGQQ7WhL8gU3Gu1sHdc92iW3I9mUKmfpMonmHbghXRfqX_7_k1GugB8belenv_OWs1VIbmNOYHBInSNA7je09iOIHOnOkpxE8XFzt3ZmF6JGZXL_zJkl-ud2tGKhX7K6mZskXT1uf_y10rerFhRNKxs__6uZP1Y6F2eQWMXg15uOsnewwTJ3Kckrlxi14DH9wMEKmddAesUdWY6eEV547whTKIt9oAQ_7AlfWOcQ5lh9QVna6e1F8VGVuUIyEAsTkgmNb_Q8tsbLOT_rYcr0QxToA_vB8K8DGIBE=">https://www.datasci.com/products/behavior/vivamars-mobile-activity-rack-system</a>.
MCS&#x2122; Mesh MEA&#x2122; Organoid Platform
The Company will also exhibit its new organoid-centric mesh Microelectrode Array (MEA) platform. Expanding on its recognized leadership position in&nbsp;in-vitro&nbsp;MEA products, the new Mesh MEA&#x2122; platform allows researchers to capture precise electrophysiology measurements from inside the living organoid in real time. The new Mesh MEA platform is designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology. For more information on our mesh MEA products and organoid research, visit our website at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=V8ttPoHOw-EWSx9Um07ZY0iuEan2Nwz07whRvDUdm_kW3beeznFV1znI6_gTvOh8nPMNBCi7hBm9WehQMZsDeO35Xn1fUycFeUy3Iv2CC_GU-gn3kLGkjQhYRf__qmRKVAfy7Ce1gpF3ho_RaBmDGBTopt7ArTeO5niLrZ8mxSoUAFyHjBE1yzbb9Pvqo1oRVYJPvJO-xs1o9rgSP9oWAGmutXqxsTKU6ZTpxHZynJjUd2s6vE1vjhxolRUm4bKPuT-BF3EOYBmBa1YgwIFju-sphUvfbnyZhCQJX6KW8NtHBZ-QCeBosw8qI_8Y7nwH997PukKWrfzyJ_Pext5o-l3EMzMaerdDkPu--TN3ETXM8hfyuCTb6Wmhncy_8lg3yDPFDXBDxlUUara_QRaXobWffyPUb35S3ikhJ1_ekoepjvWUaDPakqiWX1lXpXkruEOiz0PjGVty_1u_6qjFtA==">https://www.harvardbioscience.com/applications/organoid-research</a>.
Solutions for New Therapy Development
Jim Green, Harvard Bioscience Chairman and CEO, said, "We are pleased to offer our CRO, pharma, and biotech customers innovative products designed to reduce cycle times, improve throughput, and reduce time to market. Looking to the future, I'm especially excited by the potential of our Ponemah platform to advance the use of emerging artificial intelligence (AI) and machine learning technologies to streamline data analysis and reporting in applications such as toxicology and organoid testing."
Serge Savard, Harvard Bioscience Vice President of Product Management, said, "By integrating these new applications in a single data management platform, our Ponemah system provides a proven solution for preclinical testing. And, with the emergence of new machine learning technologies and their potential to automate the analysis and review of large data sets, we are already starting to receive customer interest in extending the Ponemah platform to incorporate these technologies."
Booth at Society of Toxicology
The Company will be exhibiting a range of solutions at Society of Toxicology booth #2304, at the Salt Palace Convention Center (Salt Lake City, UT). Representatives will be present during exhibit hours from Monday, March 11, 2024 through Wednesday, March 13, 2024.

Biotech

General

Harvard Bioscience To Showcase Latest Solutions For Preclinical And Organoid Applications At Society Of Toxicology Meeting

Health Care

Considering Headwinds In Asia, Harvard Bioscience Expects FY23 Revenue To Be Approximately Flat As Compared To 2022 Versus $116M-$120M Expected Earlier And Consensus Of $116.95M

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.04 by 75 percent. This is a 200 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $25.36 million which missed the analyst consensus estimate of $28.02 million by 9.48 percent. This is a 5.79 percent decrease over sales of $26.92 million the same period last year.

Harvard Bioscience Q3 Adjusted EPS $0.01 Misses $0.04 Estimate, Sales $25.36M Miss $28.02M Estimate

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) is set to give its latest quarterly earnings report on Tuesday, 2023-11-07. Here's what investors need to know before the announcement.
Analysts estimate that Harvard Bioscience will report an earnings per share (EPS) of $0.04. 
Harvard Bioscience bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.01, which was followed by a 1.81% drop in the share price the next day.
Here's a look at Harvard Bioscience's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.05</td>
<td>0.05</td>
<td>0.03</td>
<td>0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.06</td>
<td>0.04</td>
<td>-0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.81%</td>
<td>6.48%</td>
<td>0.38%</td>
<td>-9.5%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1699297323_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Harvard Bioscience were trading at $4.3 as of November 03. Over the last 52-week period, shares are up 75.21%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/HBIO/earnings">To track all earnings releases for Harvard Bioscience visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Harvard Bioscience

Includes dedicated version for integration with Ponemah data management software from Data Sciences International (DSI) &nbsp;
Expands reach of unique, non-invasive wearable monitoring for pre-clinical research across North American and European markets
HOLLISTON, Mass. and LYON, France, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) and Etisense announced today that they have entered into an agreement to offer DECRO&#xAE;, Etisense's non-invasive telemetry jacket and associated physiological monitoring software, to a broad range of pre-clinical customers in the North American and European markets.
Harvard Bioscience's Data Sciences International (DSI) pre-clinical business will serve as the exclusive distributor of Etisense's line of DECRO telemetry jackets and software in North America, the United Kingdom, and Ireland. Etisense will also supply a dedicated version of its DECRO telemetry jackets to be marketed by DSI in North America and Europe. These telemetry jackets, which will expand DSI's Jacketed External Telemetry (JET&#x2122;) product line, will be specially adapted to integrate with DSI's industry leading Ponemah&#x2122; monitoring and data management software.
DECRO is the first and only of its kind wearable respiratory, cardiac and physical activity monitoring solution for small mammalian models, answering unmet scientific and ethical needs in preclinical research. DECRO provides physiological endpoints required in safety-pharmacology, pre-IND toxicology studies of new drug candidates or in pathological research models, without using invasive or restraining techniques.
This innovative jacket enables low noise&nbsp;surface electrocardiogram&nbsp;(ECG) and high resolution Respiratory Inductive Plethysmography (RIP) with sensors integrated on the jacket and features an inertial motion unit to assess physical activity while the models move and live freely within study programs, supporting more true-to-life results.
For DSI's JET product line, the DECRO jacket solution will be integrated with DSI's Ponemah software platform, the industry's premier data acquisition and analysis platform, which supports continuous data acquisition from many subjects and signal types. The Ponemah platform is designed to meet a broad range of pre-clinical research needs, including for contract research organization (CRO) and pharmaceutical customers. The Ponemah software is available in both good laboratory practice (GLP) compliant and non-GLP compliant versions.
Jim Green, Harvard Bioscience President and CEO, said, "Our relationship with Etisense marks another step in maintaining DSI's leadership in pre-clinical research and aligns with Harvard Bioscience's vision to meet the needs of our larger industrial customers such as CROs and pharma companies, as well as leading academic and government labs."
Serge Savard, Harvard Bioscience Vice President of Product Management, said, "By integrating Etisense's jacketed solution into our DSI portfolio, we further enhance our offering to toxicology research customers with simplified access to physiological endpoints. Etisense's solution brings to customers a unique offering, either with Etisense's DECRO as a standalone solution or integrated with DSI's Ponemah, opening the possibilities for combined recordings with behavior studies, by using our recently announced new behavioral monitoring system."
"We're thrilled that this collaboration will bring non-invasive, small-mammal monitoring to customers across academic and industrial sectors, expanding our reach beyond Europe into North American markets." said Timothé Flenet, PhD, CEO of Etisense. "And with Harvard Bioscience, there's no better scientific, technical, and commercial portfolio to which we can contribute, to ensure more researchers can generate results with confidence and serenity."
Under the new agreement, DSI will serve as the exclusive distributor of Etisense's DECRO solution and DSI's integrated JET - Ponemah product in the United States, Canada, the United Kingdom, and Ireland. In the European Union (outside of Ireland), Etisense will continue commercializing its DECRO product line, while DSI will commercialize the integrated solution. DECRO is available immediately and will be transferrable to and interoperable with DSI's JET integration once available. The companies target first deliveries of the JET integration with Ponemah in the spring of 2024.
For product inquiries or orders:
For US, Canada, UK, and Ireland, please contact <a href="https://www.globenewswire.com/Tracker?data=-h3n8MVh1OBE-k3xoC2Wpn5hHwWozuvO01NEg_odMoPnd5DX4ZzuCHIDCYkbjHP6py_eP4wM4nwQa08uVBUkeNN8AMHVusLjhxiSHy4aaIk=">Sales@datasci.com</a>.
For Europe, please contact <a href="https://www.globenewswire.com/Tracker?data=POzdMDKRbYtgobmHcpjfN50Z0GbN2C9Oj9UUAIlTVHkBsad22ZCVJsjFVbyaVu2ud6AhoIzjepLIewwr7XG4LobwwtIky_mQYVH5JmG4-Tc=">corinne.simon@etisense.com</a> at Etisense, or <a href="https://www.globenewswire.com/Tracker?data=-h3n8MVh1OBE-k3xoC2Wpl8OGunNfE1eEi-dtjrRjM_fkTK-P_vaNGpa4X8VwHv0nBgobeA2H88IqkjILWt1ro92YisR4XnL4TNB1-bDM8I=">Sales@datasci.com</a> at DSI.

Contracts

Global

Harvard Bioscience And Etisense Announce Agreement For Supply And Distribution Of DECRO Miniature Telemetry Jacket Platform For Pre-Clinical Research

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock increased by 71.0% to $2.48 during Wednesday's pre-market session. The company's market cap stands at $4.1 million. </li>
<li>Aravive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAV#NASDAQ">ARAV</a>) stock moved upwards by 21.13% to $0.14. The market value of their outstanding shares is at $10.6 million. </li>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) stock increased by 18.81% to $1.2. The company's market cap stands at $3.8 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) stock rose 14.17% to $4.59. The company's market cap stands at $170.5 million. </li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares increased by 12.01% to $0.82. The company's market cap stands at $18.6 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) stock moved upwards by 11.96% to $4.96. The company's market cap stands at $211.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) stock decreased by 78.3% to $0.31 during Wednesday's pre-market session. The company's market cap stands at $79.5 million. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) stock declined by 24.61% to $0.96. The market value of their outstanding shares is at $94.7 million. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) stock decreased by 12.83% to $2.65. The market value of their outstanding shares is at $67.7 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares declined by 11.75% to $2.63. The company's market cap stands at $3.8 million. </li>
<li>LENSAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNSR#NASDAQ">LNSR</a>) stock declined by 11.72% to $3.09. The market value of their outstanding shares is at $34.7 million. </li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) stock decreased by 11.64% to $11.24. The company's market cap stands at $13.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACOR

AEON

ARAV

DRMA

FGEN

LNSR

NAOV

OKYO

OTLK

TIVC

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

This expected growth anticipates an approximate 4 percentage point headwind from discontinued products.

Harvard Bioscience Expects FY23 Revenues Of $116M-$120M; Consensus $120.76M

Riverwater Micro Opportunities Strategy Q1 2024 Commentary

Harvard Bioscience Non-GAAP EPS of $0.00 misses by $0.05, revenue of $23.1M misses by $3.3M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Harvard Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/hbio-stock-quote/">HBIO</a>) just reported results for the second quarter of 2024.<ul><li>The company did not report any EPS for the quarter.</li><li>The company reported revenue of $23.10 million.</li><li>This was 12.51% worse than the analyst estimate for revenue of $26.40 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/hbio-stock-earnings-harvard-bioscience-for-q2-of-2024/">HBIO Stock Earnings: Harvard Bioscience Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HBIO Stock Earnings: Harvard Bioscience Misses Revenue for Q2 2024

Harvard Bioscience, Inc. (HBIO) Q2 2024 Earnings Call Transcript

With the growing demand for innovative healthcare services, increasing spending, and rising tech adoption, the healthcare market is booming. Amid this backdrop, investors could check out quality healthcare stocks ACADIA Pharmaceuticals (ACAD), Harvard Bioscience (HBIO), and LAVA Therapeutics (LVTX), which have significant upside potential. Continue reading... Given the growing healthcare expenditure globally due to the rising aging population and growing prevalence of chronic and rare diseases, coupled with innovative solutions, the healthcare industry is positioned for continued growth and expansion. Also, advanced technologies like AI and IoT are transforming the market.
Given the industry's rosy prospects, it could be wise to invest in fundamentally strong healthcare stocks ACADIA Pharmaceuticals Inc. (<a href="https://stocknews.com/stock/ACAD/">ACAD</a>), Harvard Bioscience, Inc. (<a href="https://stocknews.com/stock/HBIO/">HBIO</a>), and LAVA Therapeutics N.V. (<a href="https://stocknews.com/stock/LVTX/">LVTX</a>) poised for significant upside.
<a href="https://www.healthsystemtracker.org/brief/policy-issues-and-trends-2024/#Total%20out-of-pocket%20retail%20prescription%20drug%20spending,%20projections%20before%20&amp;amp;%20after%20passage%20of%20the%20Inflation%20Reduction%20Act">Healthcare spending in the U.S. is expected to grow by 5%</a> between 2023 and 2024, reaching $4.90 trillion.
The healthcare market is transforming with constantly evolving government regulations and policies, <a href="https://appinventiv.com/blog/healthcare-app-trends/">innovative solutions, and rapid technological advancements</a> paving new directions for the industry. Emerging healthcare technologies like artificial intelligence, IoT, and blockchain offer advantages for both patients and practitioners by lowering costs and increasing efficiency.
As per Statista, revenue in the pharmaceuticals market is projected to hit $1.15 trillion in 2024. In global comparison, the highest revenue will be generated in the U.S. owing to advanced healthcare infrastructure and strong R&amp;D capabilities of nearly $630.30 billion. The <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">global pharmaceuticals market revenue</a> is anticipated to increase at a CAGR of 4.7%, reaching $1.45 trillion by 2029.
Further, the global AI in healthcare market is estimated to value $148.40 billion by 2029, expanding at a <a href="https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-healthcare-market-54679303.html">CAGR of 48.1%</a> driven by the need to reduce costs, increasing partnerships and collaborations among healthcare companies, and the growing demand for improvised healthcare services.
Moreover, investors' interest in the healthcare industry is evident from SPDR Select Sector Fund - Health Care (<a href="https://stocknews.com/stock/XLV/">XLV</a>) 20.7% return over the past year.
Given the industry's bright prospects, healthcare stocks like ACAD, HBIO, and LVTX look poised to soar.
Let's discuss the fundamentals of these stocks in detail:
ACADIA Pharmaceuticals Inc. (<a href="https://stocknews.com/stock/ACAD/">ACAD</a>)
ACAD is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases.
On July 18, ACAD reported the published results from the journal Med regarding the two open-label extension studies, LILAC-1&#x2122; and LILAC-2&#x2122;, which showed that patients treated with DAYBUE&#x2122; who completed these studies experienced improvement in Rett symptoms as measured by the Rett Syndrome Behaviour Questionnaire.
For the second quarter that ended June 30, 2024, ACAD's <a href="https://www.investopedia.com/terms/r/revenue.asp">total revenues</a> increased 46.4% year-over-year to $241.96 million. Its income from operations rose 902.2% from the year-ago value to $30.44 million. The company's net income and EPS came in at $33.39 million and $0.20, up 2897.2% and 1900% from the prior year's quarter, respectively.
In addition, the company's cash, cash equivalents, and investment securities were $500.94 million as of June 30, 2024, compared to $438.86 million as of December 31, 2023.
Street expects ACAD's revenue for the fiscal year ending December 2025 to increase 11.4% year-over-year to $1.06 billion. Its EPS for fiscal 2025 is expected to rise 56.1% year-over-year to $0.85. Also, the company topped the consensus revenue and EPS estimates in three of the trailing four quarters.
Shares of ACAD have declined marginally over the past month to close the last trading session at $15.84. The average analyst price target of $26.93 indicates a <a href="https://www.tipranks.com/stocks/acad/forecast">70% upside potential</a>.
ACAD's robust growth prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has an A grade for Growth, Value, and Quality. Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, ACAD is ranked #15 out of 157 stocks.
<a href="https://stocknews.com/stock/ACAD/">Click here</a> to access additional ratings of ACAD for Sentiment, Stability, and Momentum.
Harvard Bioscience, Inc. (<a href="https://stocknews.com/stock/HBIO/">HBIO</a>)
HBIO develops, manufactures, and sells technologies, products, and services for life science applications internationally. It offers cellular and molecular technology products, electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular-level testing and research.
During the second quarter, HBIO launched its latest product innovations. These included the DSI&#x2122; Ponemah&#x2122; data management platform, which provides an integrated preclinical solutions. It also launched SoHo&#x2122; implantable real-time telemetry for small animal models, VivaMARS&#x2122;, which is an activity monitoring system.
The new solutions for CROs, pharma, and biotech streamline testing and enable fundamental advancements in preclinical and organoid-focused therapy development.
HBIO reported revenues of $23.10 million during the second quarter that ended June 30, 2024, and its gross profit was $13.22 million. The company's adjusted operating stood at $818 thousand for the quarter. The company's cash and cash equivalents and total assets came in at $4.05 million and $128.91 million as of June 30, 2024.
Analysts expect HBIO's revenue for the fiscal year (ending December 2025) to increase 9.3% year-over-year to $106.85 million, and its EPS for the same year is expected to grow 100% year-over-year to $0.15.
HBIO's shares have plunged 10.9% over the past month to close the last trading session at $2.70. Wall Street analysts expect the stock to hit $6.25 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/hbio/forecast">upside of 131.5%</a>.
HBIO's sound fundamentals are reflected in its POWR Ratings. The stock has a B grade for Value. Within the <a href="https://stocknews.com/category/medical-diagnostics-research/">Medical – Diagnostics/Research</a> industry, HBIO is ranked #20 among the 39 stocks.
In addition to the POWR Ratings we've stated above, we also have HBIO ratings for Quality, Growth, Momentum, Stability, and Sentiment. Get all HBIO ratings <a href="https://stocknews.com/stock/HBIO/">here</a>.
LAVA Therapeutics N.V. (<a href="https://stocknews.com/stock/LVTX/">LVTX</a>)
Headquartered in Utrecht, Netherlands, LVTX is a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
During the second quarter, LVTX reported continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combination. It also mentioned the safety profile for LAVA-1207.
During the six months, which ended June 30, 2024, LVTX's revenue from contracts with customers increased 9.9% year-over-year to $6.99 million. Its gross profit grew 129.6% from the year-ago value to $6.99 million. The company's total non-operating income came in at $2.62 million, reflecting growth of 327.8% year-over-year.
Furthermore, the company's cash and cash equivalents and total assets stood at $35.09 million and $92.28 million as of June 30, 2024.
LVTX's stock has soared 11.2% over the past year to close the last trading session at $1.69. Wall Street analysts expect the stock to hit $6 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/lvtx/forecast">upside of 255%</a>.
LVTX's POWR Ratings reflect its robust outlook. LVTX has an A grade for Sentiment. It also has a B grade for Value. It is ranked #73 among the 335 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
<a href="https://stocknews.com/stock/LVTX/">Click here</a> to access additional LVTX ratings for Growth, Stability, Quality, and Momentum.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
ACAD shares were trading at $15.35 per share on Wednesday afternoon, down $0.49 (-3.09%). Year-to-date, ACAD has declined -50.97%, versus a 21.01% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/acad-hbio-lvtx-3-healthcare-stocks-analysts-expect-to-rally-over-50/>3 Healthcare Stocks Analysts Expect to Rally Over 50%</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks Analysts Expect to Rally Over 50%

Given the challenging market environment, the company now expects Q4 2024 revenues of $23 to $26 million. The Company expects Q4 2024 gross margins...

Harvard Bioscience sees Q4 revenue $23M-$26M, consensus $28.5M

Reports Q3 revenue $22.0M, consensus $25.3M. Jim Green, Chairman and CEO, said, "Our third quarter revenues continued to reflect the effects of the...

Harvard Bioscience reports Q3 EPS (2c), consensus 3c

Harvard Bioscience Non-GAAP EPS of -$0.02 misses by $0.03, revenue of $21.97M misses by $1.73M

ACAD

CRAI

HDSN

LVTX

NYCB

PGYWW

Press Releases

Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference

Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024

Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024

Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET

Harvard Bioscience Announces Second Quarter 2024 Financial Results

Harvard Bioscience, Inc. to Participate in the Sidoti Small Cap Virtual Conference

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting

Harvard Bioscience to Showcase Innovative Technologies at Society for Neuroscience (SfN) Annual Meeting 2024

Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET

Comments

Harvard Bioscience

Noticias

Últimas noticias sobre Harvard Bioscience (NASDAQ:HBIO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL